Skip to main content
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. — Investor Relations & Filings

Ticker · KROS ISIN · US4923271013 US Professional, scientific and technical activities
Filings indexed 474 across all filing types
Latest filing 2026-04-22 Annual Report
Country US United States of America
Listing US KROS

About Keros Therapeutics, Inc.

https://www.kerostx.com/

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics. The company develops engineered protein therapeutics designed to address a wide range of disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) superfamily of proteins. Its approach aims to selectively and potently modulate these signaling pathways to treat the underlying causes of various hematological and musculoskeletal diseases.

Recent filings

Filing Released Lang Actions
ARS - Keros Therapeutics, Inc. (0001664710) (Filer)
Annual Report
2026-04-22 English
DEF 14A - Keros Therapeutics, Inc. (0001664710) (Filer)
Proxy Solicitation & Information Statement
2026-04-22 English
8-K - KEROS THERAPEUTICS, INC. (0001664710) (Filer)
Regulatory Filings
2026-03-04 English
10-K - KEROS THERAPEUTICS, INC. (0001664710) (Filer)
Annual Report FY 2025
2026-03-04 English
8-K - KEROS THERAPEUTICS, INC. (0001664710) (Filer)
Regulatory Filings
2026-03-04 English
4 - KEROS THERAPEUTICS, INC. (0001664710) (Filer)
Director's Dealing
2026-02-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.